Cargando…

Anthracyclines inhibit SARS-CoV-2 infection

Vaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 const...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhen, Pan, Qinghua, Ma, Ling, Zhao, Jianyuan, McIntosh, Fiona, Liu, Zhenlong, Ding, Shilei, Lin, Rongtuan, Cen, Shan, Finzi, Andrés, Liang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305762/
https://www.ncbi.nlm.nih.gov/pubmed/37379907
http://dx.doi.org/10.1016/j.virusres.2023.199164
_version_ 1785065807658614784
author Wang, Zhen
Pan, Qinghua
Ma, Ling
Zhao, Jianyuan
McIntosh, Fiona
Liu, Zhenlong
Ding, Shilei
Lin, Rongtuan
Cen, Shan
Finzi, Andrés
Liang, Chen
author_facet Wang, Zhen
Pan, Qinghua
Ma, Ling
Zhao, Jianyuan
McIntosh, Fiona
Liu, Zhenlong
Ding, Shilei
Lin, Rongtuan
Cen, Shan
Finzi, Andrés
Liang, Chen
author_sort Wang, Zhen
collection PubMed
description Vaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 constantly develops drug resistance mutations. In addition, SARS-CoV-2 drugs have the potential to be repurposed to inhibit new human coronaviruses, thus help to prepare for future coronavirus outbreaks. We have screened a library of microbial metabolites to discover new SARS-CoV-2 inhibitors. To facilitate this screening effort, we generated a recombinant SARS-CoV-2 Delta variant carrying the nano luciferase as a reporter for measuring viral infection. Six compounds were found to inhibit SARS-CoV-2 at the half maximal inhibitory concentration (IC50) below 1 μM, including the anthracycline drug aclarubicin that markedly reduced viral RNA-dependent RNA polymerase (RdRp)-mediated gene expression, whereas other anthracyclines inhibited SARS-CoV-2 by activating the expression of interferon and antiviral genes. As the most commonly prescribed anti-cancer drugs, anthracyclines hold the promise of becoming new SARS-CoV-2 inhibitors.
format Online
Article
Text
id pubmed-10305762
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103057622023-06-29 Anthracyclines inhibit SARS-CoV-2 infection Wang, Zhen Pan, Qinghua Ma, Ling Zhao, Jianyuan McIntosh, Fiona Liu, Zhenlong Ding, Shilei Lin, Rongtuan Cen, Shan Finzi, Andrés Liang, Chen Virus Res Article Vaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 constantly develops drug resistance mutations. In addition, SARS-CoV-2 drugs have the potential to be repurposed to inhibit new human coronaviruses, thus help to prepare for future coronavirus outbreaks. We have screened a library of microbial metabolites to discover new SARS-CoV-2 inhibitors. To facilitate this screening effort, we generated a recombinant SARS-CoV-2 Delta variant carrying the nano luciferase as a reporter for measuring viral infection. Six compounds were found to inhibit SARS-CoV-2 at the half maximal inhibitory concentration (IC50) below 1 μM, including the anthracycline drug aclarubicin that markedly reduced viral RNA-dependent RNA polymerase (RdRp)-mediated gene expression, whereas other anthracyclines inhibited SARS-CoV-2 by activating the expression of interferon and antiviral genes. As the most commonly prescribed anti-cancer drugs, anthracyclines hold the promise of becoming new SARS-CoV-2 inhibitors. Elsevier 2023-06-28 /pmc/articles/PMC10305762/ /pubmed/37379907 http://dx.doi.org/10.1016/j.virusres.2023.199164 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Wang, Zhen
Pan, Qinghua
Ma, Ling
Zhao, Jianyuan
McIntosh, Fiona
Liu, Zhenlong
Ding, Shilei
Lin, Rongtuan
Cen, Shan
Finzi, Andrés
Liang, Chen
Anthracyclines inhibit SARS-CoV-2 infection
title Anthracyclines inhibit SARS-CoV-2 infection
title_full Anthracyclines inhibit SARS-CoV-2 infection
title_fullStr Anthracyclines inhibit SARS-CoV-2 infection
title_full_unstemmed Anthracyclines inhibit SARS-CoV-2 infection
title_short Anthracyclines inhibit SARS-CoV-2 infection
title_sort anthracyclines inhibit sars-cov-2 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305762/
https://www.ncbi.nlm.nih.gov/pubmed/37379907
http://dx.doi.org/10.1016/j.virusres.2023.199164
work_keys_str_mv AT wangzhen anthracyclinesinhibitsarscov2infection
AT panqinghua anthracyclinesinhibitsarscov2infection
AT maling anthracyclinesinhibitsarscov2infection
AT zhaojianyuan anthracyclinesinhibitsarscov2infection
AT mcintoshfiona anthracyclinesinhibitsarscov2infection
AT liuzhenlong anthracyclinesinhibitsarscov2infection
AT dingshilei anthracyclinesinhibitsarscov2infection
AT linrongtuan anthracyclinesinhibitsarscov2infection
AT censhan anthracyclinesinhibitsarscov2infection
AT finziandres anthracyclinesinhibitsarscov2infection
AT liangchen anthracyclinesinhibitsarscov2infection